Microglial NLRP3 Inflammasome Activation upon TLR2 and TLR5 Ligation by Distinct α-Synuclein Assemblies

Hannah Scheiblich1,2, Luc Bousset3, Stephanie Schwartz1

  • 1Department of Neurodegenerative Disease and Gerontopsychiatry/Neurology, University of Bonn Medical Center, Bonn, Germany.

Insights

Parkinson's disease involves abnormal alpha-synuclein (α-syn) protein. Microglia immune cells activate the NLRP3 inflammasome, hindering α-syn clearance, but NLRP3 inhibition improves its degradation.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder linked to abnormal alpha-synuclein (α-syn) aggregation.
  • Microglia, the brain's immune cells, respond to misfolded proteins via pattern recognition receptors and signaling pathways.

Purpose of the Study:

  • To investigate how different forms of α-syn activate primary microglia.
  • To understand the role of the NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome in α-syn clearance by microglia.

Main Methods:

  • Primary microglia isolated from wild-type mice were exposed to distinct α-syn forms (monomers and oligomers).
  • Activation of the NLRP3 inflammasome was assessed, along with α-syn internalization and degradation.
  • The effects of NLRP3 inhibition (using CRID3 sodium salt) and NLRP3 deficiency on α-syn clearance were evaluated.

Main Results:

  • Both α-syn monomers and oligomers activated the NLRP3 inflammasome through TLR2 and TLR5 ligation.
  • Microglia efficiently internalized α-syn but showed impaired degradation.
  • NLRP3 inhibition and deficiency significantly enhanced the clearance of α-syn oligomers.

Conclusions:

  • Distinct α-syn forms differentially activate microglial NLRP3 inflammasome signaling.
  • This activation compromises α-syn degradation, contributing to PD pathology.
  • Inhibiting NLRP3 presents a potential therapeutic strategy to improve α-syn clearance in Parkinson's disease.

Related Concept Videos